SCHEMBL5745787

SCHEMBL5745787

CCN1c2nc(C(F)(F)F)ccc2NC(=O)c2cc(Br)cnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 3/20 0.37
CYP2C19 P33261 3/20 0.37
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
TGM2 P21980 1/20 0.34
CES1 P23141 1/20 0.34
JUN P05412 4/20 0.34
NFKB1 P19838 4/20 0.34
NFKB2 Q00653 4/20 0.34
RELA Q04206 4/20 0.34
CYP1B1 Q16678 1/20 0.33
ADRA2B P18089 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30
AGTR1 P30556 1/20 0.30
LRRK2 Q5S007 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744385 0.86 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4035355 0.84 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5744876 0.82 CYP3A4 (0.42) CYP3A4CYP2C9CYP2C19CYP1A2CES1
SCHEMBL4031265 0.79 RAB9A (0.43) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5746722 0.72 CYP3A4 (0.65) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6961619 0.70 CYP3A4 (0.44) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL5743837 0.70 CYP3A4 (0.50) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL6965170 0.69 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL7740393 0.68 CYP3A4 (0.47) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6
SCHEMBL4035380 0.67 CYP3A4 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655300-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-05-10 EP disclosed
EP-1294720-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-04-05 EP disclosed
US-6420359-B1 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-07-16 US disclosed
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors REV1, POLR2H, POLR2E CYP3A4 560/4885CYP2C9 1933/4885CYP2C19 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.